Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs

被引：0
|
作者：
Schultz, RM [1 ]
Chen, VJ [1 ]
Bewley, JR [1 ]
Roberts, EF [1 ]
Shih, C [1 ]
Dempsey, JA [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA
来源：
SEMINARS IN ONCOLOGY | 1999年 / 26卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 73
页数：6
相关论文
共 50 条
  • [21] Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
    Miller, KD
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Shulman, LN
    Thornton, D
    Rowinsky, E
    Loehrer, PJ
    ANNALS OF ONCOLOGY, 2000, 11 (01) : 101 - 103
  • [22] Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
    Thödtmann, R
    Depenbrock, H
    Dumez, H
    Blatter, J
    Johnson, RD
    van Oosterom, A
    Hanauske, AR
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3009 - 3016
  • [23] Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514
    Zervos, PH
    Allen, RH
    Thornton, DE
    Thiem, PA
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 62 - 62
  • [24] Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)
    Clarke, S
    Millward, M
    Findlay, M
    Ackland, S
    Hosie, D
    Abratt, R
    Goedhals, L
    ANNALS OF ONCOLOGY, 1998, 9 : 86 - 87
  • [25] Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma
    Tonkinson, JL
    Worzalla, JF
    Teng, CH
    Mendelsohn, LG
    CANCER RESEARCH, 1999, 59 (15) : 3671 - 3676
  • [26] Activity of multitargeted antifolate (Pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma - Results from a phase II study
    John, W
    Picus, J
    Blanke, CD
    Clark, JW
    Schulman, LN
    Rowinsky, EK
    Thornton, DE
    Loehrer, PJ
    CANCER, 2000, 88 (08) : 1807 - 1813
  • [27] Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)
    Shih, C
    Habeck, LL
    Mendelsohn, LG
    Chen, VJ
    Schulz, RM
    ADVANCES IN ENZYME REGULATION, VOL 38, 1998, 38 : 135 - 152
  • [28] A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
    Rinaldi, DA
    Kuhn, JG
    Burris, HA
    Dorr, FA
    Rodriguez, G
    Eckhardt, SG
    Jones, S
    Woodworth, JR
    Baker, S
    Langley, C
    Mascorro, D
    Abrahams, T
    Von Hoff, DD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (05) : 372 - 380
  • [29] A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
    David A. Rinaldi
    John G. Kuhn
    Howard A. Burris
    F. Andrew Dorr
    Gladys Rodriguez
    S. Gail Eckhardt
    Suzanne Jones
    James R. Woodworth
    Sharyn Baker
    Connie Langley
    David Mascorro
    Trent Abrahams
    Daniel D. Von Hoff
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 372 - 380
  • [30] A phase II trial of multi-targeted antifolate (MTA) (LY231514) in patients with unresectable pancreatic cancer
    Miller, KD
    Loehrer, PJ
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Schulman, LN
    Burris, H
    Thornton, D
    ANNALS OF ONCOLOGY, 1998, 9 : 46 - 46
12345